Company Announcement no. 10/2009
To: NASDAQ OMX Copenhagen Hørsholm, Denmark, April 16,2009
Major Shareholder Announcement
Hørsholm, Denmark, April 16 2009; In accordance with Section 29 of the
Securities Trading Act LifeCycle Pharma A/S (OMX: LCP) today announced that LCP
has received a notification from ATP and ATP Invest that it after purchase has
shareholdings in LCP of 2,873,215 shares of nom. DKK 1, corresponding to 5.09%
of the share capital and the voting rights in LCP.
For more information, please contact:
LifeCycle Pharma A/S
Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: PSK@lcpharma.com
About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a cholesterol-lowering
product, Fenoglide™, currently on the U.S. market and a diversified near- and
medium-term pipeline with four product candidates in clinical trials and a
number of projects in preclinical development. LCP is listed on the NASDAQ OMX
Copenhagen under the trading symbol (OMX: LCP).
For further information, please visit www.lcpharma.com.
